FDA grants fast track designation to HLD-0915 in mCRPC by admin_63069 | Sep 17, 2025 | News You Can Use Preclinical studies demonstrated tumor shrinkage and PSA decline with HLD-0915, showing a favorable therapeutic index, even in drug-resistant models.